1cP-MiPLA
1cP-MiPLA is a semisynthetic psychedelic of the lysergamide class that first emerged as a novel designer drug around 2020.1 It is a structural analog of MiPLA and is suspected to act as a prodrug for that compound, though insufficient data currently exists to confirm this relationship.2 As a research chemical with limited documented human use, its safety profile and pharmacological properties remain poorly characterized.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
1cP-MiPLA is believed to act as a prodrug for MiPLA, and its subjective effects are correspondingly reported to closely mirror those of its parent compound. The experience is that of a classic lysergamide psychedelic in the vein of LSD, though it is generally described as gentler, shorter-lasting, and less mentally demanding than LSD itself. Formal documentation of this compound remains minimal, and its effect profile is inferred largely from user reports and its relationship to MiPLA.
Physical
The body load is generally described as light, consisting primarily of mild stimulation alongside standard serotonergic psychedelic signs such as pupil dilation.
Cognitive
The headspace is often characterized as relatively clear and easygoing, with euphoria and an altered sense of time, and with less of the anxiety and cognitive intensity associated with LSD.
Visual
Visual effects are characteristic of lysergamide psychedelics but are typically milder than those of LSD at equivalent doses.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
1cP-MiPLA is believed to act as a partial agonist at serotonin 5-HT2A receptors, which is thought to underlie its psychedelic effects. It is also assumed to have broader serotonin receptor agonist activity, though specific binding data have not been reported2.
Pharmacokinetics
1cP-MiPLA is assumed to act as a prodrug of MiPLA, undergoing deacylation of its 1-cyclopropionyl group to yield the parent compound. This prodrug relationship is analogous to that of 1cP-LSD and LSD3, though it has not been confirmed for 1cP-MiPLA specifically.2
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Serotonergic psychedelics (LSD, psilocybin, mescaline, DMT), Other lysergamides
Harm Potential
Addiction & Dependence
Psychological
Extremely LowAssumed to be non-habit-forming based on its similarity to LSD4; the desire to use may actually decrease with repeated administration. No formal studies have been conducted.
Physical
Extremely LowNo evidence of physical dependence potential. Like LSD, 1cP-MiPLA is not associated with withdrawal symptoms or compulsive physical need for the substance.5
Psychosis Risk
May act as a potential trigger for psychotic episodes in individuals with underlying psychiatric conditions or family history of mental illness.5 Adverse psychological reactions including delusions become more likely at higher doses, though severe psychotic episodes requiring medical attention are uncommon with this substance alone.
Seizure Risk
Seizures are reported rarely and are thought to mainly pose a risk in those who are genetically predisposed6, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment. Risk is extrapolated from seizures reported following LSD use.
History & Culture
1cP-MiPLA is a novel synthetic lysergamide that first emerged on online research chemical markets around 2020.1 The compound's origins remain somewhat unclear, with unverified reports attributing its initial synthesis to either Skyler Ulrich or a chemist or group operating…
Legality
By Country
References
Source Pages
Citations
- (n.d.). 1cP-MIPLA. АИПСИН. https://aipsin.com/newsubstance/562/123
- (2023). Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products. Forensic Toxicology, 41(2), 294–303. https://doi.org/10.1007/s11419-023-00661-112345
- Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, Dowling G, Dempster NM, Wallach J, Passie T, & Halberstadt AL. (2020). Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD). Drug Testing and Analysis, 12(6), 812-826. https://doi.org/10.1002/dta.27891
- Nichols DE. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.0114781
- Schlag AK, Aday J, Salam I, Neill JC, & Nutt DJ. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 36(3), 258–272. https://doi.org/10.1177/0269881121106910012
- Simonsson O, Goldberg SB, Chambers R, Osika W, Long DM, & Hendricks PS. (2022). Prevalence and associations of classic psychedelic-related seizures in a population-based sample. Drug and Alcohol Dependence, 239, 109586. https://doi.org/10.1016/j.drugalcdep.2022.1095861
- (2022). Analyses of LSD analogs in illegal products: The identification of 1cP-AL-LAD, 1cP-MIPLA and 1V-LSD. Toxicologie Analytique et Clinique, 34(3), S171. https://doi.org/10.1016/j.toxac.2022.06.2951
- (n.d.). Anlage NpSG — Änderung vom 03.07.2021 (Einführung Stoffgruppe 5.2 Δ9,10-Ergolene), Verordnung vom 28.06.2021 (BGBl. I S. 2231). buzer.de (Gesetze-Änderungsdienst, Volltext mit BGBl.-Fundstellen). https://www.buzer.de/gesetz/12250/al149920-0.htm1
- (n.d.). § 3 NpSG — Unerlaubter Umgang mit neuen psychoaktiven Stoffen. Bundesministerium der Justiz. https://www.gesetze-im-internet.de/npsg/__3.html1
- (n.d.). Постановление Правительства РФ от 30.06.1998 N 681 — Перечень наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации (ред. от 11.06.2025). Правительство Российской Федерации. https://normativ.kontur.ru/document?moduleId=1&documentId=5031951
- (n.d.). Betäubungsmittelverzeichnisverordnung (BetmVV-EDI, SR 812.121.11), Anhang 5 Verzeichnis e, Ziff. 263 Lysergsäurederivate. Eidgenössisches Departement des Innern (EDI) / Bundesrecht (admin.ch). https://res.cloudinary.com/adminch/image/private/s--aGGgd8MH--/v1773719628/Bundespublikationen/812-121-11d.pdf12
- (n.d.). 21 U.S.C. § 813 — Treatment of controlled substance analogues (Federal Analogue Act). Cornell Law School, Legal Information Institute (U.S. Code). https://www.law.cornell.edu/uscode/text/21/8131
Further Reading
Halberstadt A.L. et al. Pharmacological characterization of novel lysergamides including MiPLA. Neuropharmacology (2020)
Tanaka R. et al. Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products. Forensic Science International (2023)
TripReport.net substance overview: 1cP-MiPLA
Wagmann L. et al. Analysis of LSD analogs (1cP-MiPLA, 1cP-LSD, etc.) in seized blotters. Forensic Toxicology (2021)
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 1cP-MiPLA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.